Bausch + Lomb Corporation

Filing receipts

“Interest expense was $97 million and $94 million for the three months ended March 31, 2026 and 2025, respectively, an increase of $3 million, primarily driven by financing fees associated with the January 2026 Credit Facility Amendment, as defined below.”

“Gross product sales $ 1,992 100.0 % $ 1,866 100.0 % Provisions to reduce gross product sales to net product sales Discounts and allowances 116 5.80 % 106 5.70 % Returns 21 1.10 % 11 0.60 % Rebates 418 21.00 % 445 23.90 % Chargebacks 176 8.80 % 146 7.80 % Distribution fees 22 1.10 % 25 1.30 % Total provisions 753 37.80 % 733 39.30 % Net product sales 1,239 62.20 % 1,133 60.70 % Other revenues 5 4 Revenues $ 1,244 $ 1,137 Cash discounts and allowances, returns, rebates, chargebacks and distribution fees as a percentage of gross product sales were 37.8% and 39.3% for the three months ended March 31, 2026 and 2025, respectively, a decrease of 1.5% percentage points, and is primarily attributabl...”

“The increase was attributable to: (i) the favorable impact of foreign currencies of $42 million, (ii) increased net realized pricing of $38 million, primarily driven by our Vision Care and Pharmaceuticals segments, (iii) increased volumes of $29 million primarily from our Pharmaceuticals and Vision Care segments and (iv) incremental sales attributable to acquisitions of $1 million, within our Surgical segment.”